skip to main content
UK Health Security Agency

108CC15

108CC15

Catalogue No.

08062516

Cell Line Name

108CC15

Cell Line Description

The cell line108CC15 is formed by the fusion of mouse neuroblastoma N18TG2 and rat glioma C6-BU-1using inactivated Sendai virus. This cell line was renamed NG108-15 by Klee and Nirenberg (Proc. Natl. Acad. Sci. (1974) 71: 3474-77). ECACC has two catalogue entries for the 108CC15 cell line which differ in that they were deposited by different groups: 108CC15 from the original group that derived the cell line (ECACC catalogue number 08062516) and NG108-15 (ECACC catalogue number 88112302). Several other cell lines in the ECACC catalogue have been derived from 108CC15. This is a cholinergic hybrid cell line.

Characteristics

Receptors

Receptors for neurohormones: delta opioid, PGE1 vasoactive intestinal polypeptide, adenosine, somatostatin and acetylcholine.

Products

Long processes after treatment with dibutyryl cAMP, dense core vesicles, excitable membranes, neurotransmitter enzymes, synthesis of neurohormones and uptake of catecholamines.

Tissue of Origin

Neural

Karyotype

Modal No. varied with passage see reference

Applications

Used as a neuronal Model

Disease

Neuroblastoma/Glioma Hybrid

Culture Conditions

Cell Type

Neuronal

Subculture Routine

Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 1-2x10,000 cells/cm² using 0.05% trypsin/EDTA; 5% CO₂; 37°C. The cultures rapidly produce lactic acid through anaerobic glycolysis causing the media to become acidified. The medium must never be allowed to become acidic as cells detach in clumps and take many passages to recover. Frequent inspection of cultures is therefore required.

Culture Medium

DMEM + 2 mM glutamine + 10% Foetal Bovine Serum (FBS) HAT (0.1 mM hypoxanthine, 10 µM aminopterin and 16 µM thymidine) Cells can be cultured without HAT provided they were cultured inbetween in HT medium for 3-4 days

Growth Mode

Adherent

Additional Info

Depositor

Professor Bernd Hamprecht, Interfaculty Institute for Biochemistry, University of Tuebingen, Hoppe-Seyler Street 4, 72076 Tuebingen, Germany.

Country of Origin

Germany

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Hamprecht, (1977) Structural, electrophysiological, biochemical, and pharmacological properties of neuroblastoma-glioma cell hybrids in cell culture Int. Rev. Cytol. 49: 99-170.

Bibliography

Hamprecht et al., (1985) Culture and characteristics of hormone-responsive neuroblastoma x glioma hybrid cells. Meth. Enzymol. 109: 316-341.

Available Formats

  • Frozen

If use of this culture results in a scientific publication, it should be cited in the publication as: 108CC15 (ECACC 08062516).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.